1. Medtech Insight
  2. >>Business
  3. >>Startups & SMEs

Start-Up Spotlight: Kephalios, Simplifying Targeted Mitral Valve Repair

 
• By Tina Tan

Investors are betting on mitral valves as the next "big thing" in cardiology as interest in technologies to treat mitral regurgitation heat up among the big heart players. Competition among the developers of transcatheter mitral valve repair systems is intensifying as they jostle for attention, but start-up Kephalios believes the simplicity of its technology, which precisely targets repair of the defective valve, will help it stand out.

Start-up Spotlight

Of the estimated 4 million patients in the US and Europe suffering from severe mitral valve regurgitation, less than 4% undergo a mitral intervention to fix it annually, according to Kephalios, a French start-up seeking a slice of this pie with its Kalios balloon-adjustable TMVR system.

Mitral valve leaflets that do not close completely may allow blood to regurgitate back into the left atrium rather than pass through to the left ventricle. About 1% of the world's population is afflicted by mitral regurgitation, and about 8% to 9% of people 65 and older suffer from mitral regurgitation, but the commercial opportunity created by this large patient pool is largely untapped, so repair of the heart's mitral valve in patients is expected to be the next big opportunity in the cardiology device space. Boston Scientific Corp

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Startups & SMEs

LSX Europe: Women’s Health Education Is The Key For Unlocking VC Investment

 
• By Natasha Barrow

Flo Health was the first femtech unicorn to be valued at over $1bn. But the company faced 49 investment rejections before reaching that status, Anna Klepchukova, the company’s chief medical officer, told the LSX World Congress Europe. THENA Capital’s Esther Reynal de St Michel Richardot talked through the firm’s gender-smart investment strategy.

‘Pathologists Are Hungry For AI-Enabled Digital Pathology’

 
• By Natasha Barrow

Digital pathology makes it possible to unlock insights previously hidden to the human eye, “reshaping how we diagnose and treat patients,” said Nathan Buchbinder, co-founder and chief strategy officer at Proscia. He shared his views on the future of digital pathology and the lessons he has learned from working with pathologists.

LSX Roundup: Startups Elypta, QuantiLight And Plexaa Debut New Tech

 
• By Natasha Barrow

Back-to-back meetings at LSX? No time to attend the innovator showcase? Here is what you might have missed from medtech innovators at the LSX World Congress Europe on 29 April.

‘AI Isn’t Flying Off The Shelves In The NHS,’ Says Healthtech Startup CEO

 
• By Natasha Barrow

Vendor exhaustion, insufficient clinical-grade evidence, and outdated risk management are some of the reasons the NHS is struggling to adopt AI. Haris Shuaib, CEO of Newton's Tree, shared his insights with the audience at the “Next Frontier of Medical AI” event held at DAC Beachcroft's London office on 23 April.

More from Business

Mirvie Launches Predictive Blood Test For Preeclampsia

 
• By Marion Webb

Mirvie launched Encompass, a blood test to help identify women over age 35 who are at moderate risk for preeclampsia, and will conduct additional studies to support reimbursements from payers.

Bringing Israeli Medical Device Candidates To The Right Partners In The US

 
• By Ashley Yeo

Despite regional unrest, it is business as usual for medtech innovators and investors in Israel as evidenced by continued high-value M&A of locally developed technologies. Irit Yaniv, co-chair of the medtech session at the upcoming BioMed Israel 2025, explained the unique dynamics of Israeli medtech innovation.

SpotitEarly Raised $20.3M In New Funding To Bring AI- And Dog-Sniffing-Powered Early Cancer Detection Test To US

 
• By Marion Webb

Israeli-based SpotitEarly hopes to bring an early cancer-detection test, which uses dogs’ noses to detect compounds in exhaled breath and AI analysis, to US homes in 2026.